Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)

Peer Review reports

Original Submission
28 Feb 2022	Submitted	Original manuscript
6 Jun 2022	Reviewed	Reviewer Report - Kirsty Loudon
1 Jul 2022	Author responded	Author comments - Tania A. Smith
Resubmission - Version 2
1 Jul 2022	Submitted	Manuscript version 2
Publishing
8 Jul 2022	Editorially accepted
22 Jul 2022	Article published	10.1186/s13063-022-06533-0

Back to article page